Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Korsana Biosciences Q3 2026 Results: Net Loss of $46.4M, Loss Widens

Korsana Biosciences completed a reverse recapitalization in 2026, significantly increasing its cash position to $456.2 million through a pre-closing financing. The company reported a net loss of $77.3 million for the nine months ended September 30, 2026, driven primarily by a substantial increase in research and development expenses.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-46.4-21.7
EPS (diluted, $ a share)$-3.19$-39.49

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: KRSA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Korsana Biosciences, Inc.: key numbers

Share price
$32.50Close, Nov 17
Market cap
$1.48B
Shares outstanding
45.54MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Korsana Biosciences, Inc.

All →
7:07 AM ET 8-K
Financial Results

Korsana Biosciences Financial Results

Korsana Biosciences reported third quarter 2026 financial results, highlighting a cash position of $456.2 million following its merger with Cyclerion Therapeutics and a $380 million private placement. The company expects its current capital to fund operations into 2029 as it advances its lead Alzheimer's candidate, KRSA-028, toward Phase 1 clinical data in mid-2027.

Term
Q3 2026

“The third quarter was transformative for Korsana, providing us with the financial resources and experienced leadership team to execute our strategy. With this foundation in place, we remain focused on advancing KRSA-028 toward the clinic and building the body of evidence supporting the program, including through our first preclinical poster at CTAD later this month.”

Jonathan Violin, Ph.D., President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.